---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-028564"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:34:44.481942+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rigel settles TAVALISSE patent litigation with Annora; generic entry in Q2 2032

## Summary
- Entered settlement with Annora Pharma, Hetero Labs, and Hetero USA resolving patent litigation on TAVALISSE (fostamatinib).
- Annora receives license to sell generic version in Q2 2032 or earlier under certain circumstances.
- All ongoing litigation between Rigel and Annora in New Jersey terminated.
- CEO Raul Rodriguez cites resolution as underscoring strength of TAVALISSE intellectual property.

## SEC filing metadata
- accession: 0001104659-25-028564
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465925028564/0001104659-25-028564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465925028564/tm2510607d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-028564
- JSON: https://secwatch.observer/filing/0001104659-25-028564.json
- Plain text: https://secwatch.observer/filing/0001104659-25-028564.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.